Labeling requirements for devices (21 CFR Part 801) and UDI system MCQs With Answer

Introduction

This quiz set focuses on 21 CFR Part 801 labeling requirements and the FDA’s Unique Device Identification (UDI) system — key topics in Regulatory Aspects of Medical Devices for M.Pharm students. It explains differences between “label” and “labeling,” mandatory label elements, and the concept of adequate directions for use and required warnings. The UDI section covers the structure of a UDI (Device Identifier and Production Identifier), direct marking, recognized issuing agencies, and submission of device records to the Global Unique Device Identification Database (GUDID). These MCQs emphasize practical regulatory application, review responsibilities, and compliance implications for pharmaceutical professionals working with medical devices.

Q1. Which statement best distinguishes “label” from “labeling” under 21 CFR Part 801?

• The “label” is the immediate physical tag on the device or its container; “labeling” includes the label plus all written, printed, or graphic materials accompanying the device.
• “Label” refers to promotional brochures; “labeling” refers only to the package insert.
• “Label” means electronic record only; “labeling” means paper record only.
• “Label” and “labeling” are interchangeable terms with identical regulatory meanings.

Correct Answer: The “label” is the immediate physical tag on the device or its container; “labeling” includes the label plus all written, printed, or graphic materials accompanying the device.

Q2. Under 21 CFR Part 801, which element is generally required on the label of a medical device?

• Net quantity of contents, manufacturer name and place of business, and intended use.
• Only the manufacturer’s logo and marketing slogan.
• Clinical study results demonstrating efficacy.
• Distributor social media contact details.

Correct Answer: Net quantity of contents, manufacturer name and place of business, and intended use.

Q3. Which devices are commonly exempt from the requirement to bear “adequate directions for use” on their labeling?

• Prescription devices intended to be used only by practitioners who are trained to use them.
• Over-the-counter devices sold directly to consumers without supervision.
• All implantable devices, regardless of intended use.
• Devices marketed exclusively outside the United States.

Correct Answer: Prescription devices intended to be used only by practitioners who are trained to use them.

Q4. Which of the following best describes a UDI as required by FDA?

• A UDI is a unique numeric or alphanumeric code that includes a Device Identifier (DI) specific to a device model and a Production Identifier (PI) that conveys production information like lot or serial number.
• A UDI is a marketing campaign code used to track sales promotions.
• A UDI is a manufacturer’s internal SKU number only shown on invoices.
• A UDI is an electronic-only identifier stored in hospital IT systems and not printed on labels.

Correct Answer: A UDI is a unique numeric or alphanumeric code that includes a Device Identifier (DI) specific to a device model and a Production Identifier (PI) that conveys production information like lot or serial number.

Q5. Which entities are FDA-recognized issuing agencies for UDIs?

• GS1, HIBCC, and ICCBBA.
• ISO, ANSI, and ASTM.
• GMP, GLP, and GCP.
• CE, MHRA, and TGA.

Correct Answer: GS1, HIBCC, and ICCBBA.

Q6. What is the primary purpose of the Global Unique Device Identification Database (GUDID)?

• To store device-identification records (DI and associated device information) so that regulators, healthcare providers, and the public can access standardized device data.
• To host promotional materials and clinical trial PDFs for each device.
• To replace all labeling on the physical device.
• To assign CE marks to medical devices for the EU market.

Correct Answer: To store device-identification records (DI and associated device information) so that regulators, healthcare providers, and the public can access standardized device data.

Q7. Which of the following production identifiers (PIs) is typically included in the UDI?

• Lot or batch number, serial number, expiration date, and manufacturing date.
• Only the medical center purchasing code.
• Manufacturer’s financial account number.
• Hospital patient identification number.

Correct Answer: Lot or batch number, serial number, expiration date, and manufacturing date.

Q8. When must a UDI appear in both human-readable and automatic identification and data capture (AIDC) form on device packaging?

• When FDA UDI regulations require it for the device class and packaging level to ensure both machine-readability and human readability.
• Only when the manufacturer chooses to include it for marketing benefits.
• Never — UDI must be electronic only in the manufacturer’s records.
• Only for devices sold in Europe, not in the U.S.

Correct Answer: When FDA UDI regulations require it for the device class and packaging level to ensure both machine-readability and human readability.

Q9. For devices that are intended to be reprocessed and reused, what UDI-related requirement commonly applies?

• The device must be directly marked with a UDI (direct part marking) unless it is not technically feasible.
• The device may never have a UDI if it is reusable.
• The UDI may be printed only on the outermost shipping carton.
• The UDI requirement is waived if the device is reprocessed by the user facility.

Correct Answer: The device must be directly marked with a UDI (direct part marking) unless it is not technically feasible.

Q10. Which one of these is a potential regulatory consequence of labeling that is false or misleading under the Federal Food, Drug, and Cosmetic Act?

• The device may be deemed “misbranded,” which can lead to warning letters, recalls, or other enforcement actions.
• The device will automatically receive expedited market clearance.
• The manufacturer will be granted an exemption from future UDI submissions.
• No regulatory consequence applies for labeling issues.

Correct Answer: The device may be deemed “misbranded,” which can lead to warning letters, recalls, or other enforcement actions.

Q11. Which piece of information is submitted to GUDID by the manufacturer?

• Device Identifier (DI) and associated basic device attributes (but not the production identifier data such as lot or serial numbers).
• Every individual device’s serial number and patient usage history.
• Only marketing claims and promotional images.
• Internal financial forecasts for device sales.

Correct Answer: Device Identifier (DI) and associated basic device attributes (but not the production identifier data such as lot or serial numbers).

Q12. Which of the following best describes when a manufacturer must include the UDI on the device itself (not just packaging)?

• When the device is intended to be used more than once and reprocessed, or when it is required by FDA because the device cannot be adequately identified through packaging alone.
• Only when the device is sold through online marketplaces.
• Only when the device is classified as Class I and not for Class II or III.
• When the manufacturer wants to keep inventory records internally, not for regulatory reasons.

Correct Answer: When the device is intended to be used more than once and reprocessed, or when it is required by FDA because the device cannot be adequately identified through packaging alone.

Q13. Which of these is NOT typically considered a component of labeling under FDA regulations?

• Internal financial audit reports unrelated to device safety or use.
• Instructions for use and warnings distributed with the device.
• Package inserts and user manuals supplied with the device.
• Advertising claims that accompany the device in promotional brochures.

Correct Answer: Internal financial audit reports unrelated to device safety or use.

Q14. What format(s) of AIDC are acceptable for UDIs on device labels?

• Linear barcodes and 2D matrix barcodes (e.g., Data Matrix), depending on space and readability requirements.
• Only plain text without any machine-readable code.
• Only RFID chips are acceptable; barcodes are not allowed.
• Handwritten labels are required for traceability.

Correct Answer: Linear barcodes and 2D matrix barcodes (e.g., Data Matrix), depending on space and readability requirements.

Q15. Which of the following is true about the Device Identifier (DI)?

• The DI is a fixed portion of the UDI that identifies the specific version or model of a device and is issued by an FDA-recognized issuing agency.
• The DI changes for every individual device produced from the same model.
• The DI is only used internally and is never reported to GUDID.
• The DI is the same as the distributor’s SKU number.

Correct Answer: The DI is a fixed portion of the UDI that identifies the specific version or model of a device and is issued by an FDA-recognized issuing agency.

Q16. Which labeling statement is most consistent with FDA expectations for “intended use”?

• A clear description of the disease or condition the device is intended to diagnose, cure, mitigate, treat, or prevent, tied to how the device is used.
• An open-ended aspirational marketing message without clinical context.
• Only the manufacturing address with no clinical indication.
• A list of unrelated off-label uses recommended by the manufacturer.

Correct Answer: A clear description of the disease or condition the device is intended to diagnose, cure, mitigate, treat, or prevent, tied to how the device is used.

Q17. Which of the following scenarios may justify an exemption from direct part marking with a UDI?

• When direct marking is not technologically feasible because the device is too small or marking would interfere with device function.
• When the manufacturer prefers to reduce production costs irrespective of feasibility.
• When the device is sold only in single-use sterile packs regardless of reuse potential.
• When the device already has a UPC barcode for retail sale.

Correct Answer: When direct marking is not technologically feasible because the device is too small or marking would interfere with device function.

Q18. In regulatory review, why is it important to verify that the human-readable UDI and the AIDC representation correspond exactly?

• To ensure correct device identification in both electronic systems and manual reading, preventing errors in traceability, recalls, and adverse event investigations.
• To comply with marketing team preferences for label aesthetics.
• To allow multiple different UDIs for the same device model to increase sales tracking options.
• There is no regulatory need for correspondence between human-readable and AIDC forms.

Correct Answer: To ensure correct device identification in both electronic systems and manual reading, preventing errors in traceability, recalls, and adverse event investigations.

Q19. Which of the following best describes a situation where labeling may render a device “misbranded”?

• When labeling omits a required warning or directions for use, or contains false or misleading statements about safety or effectiveness.
• When a device is sold below the suggested retail price.
• When the device label uses colors that differ from the manufacturer’s corporate palette.
• When the manufacturer uses too many fonts on the label.

Correct Answer: When labeling omits a required warning or directions for use, or contains false or misleading statements about safety or effectiveness.

Q20. For regulatory submissions and quality systems, what is a primary benefit of implementing a correct UDI strategy?

• Improved device traceability across supply chains and healthcare settings, facilitating faster recalls, adverse event tracking, and inventory control.
• Guaranteed exemption from all future FDA inspections.
• Automatic approval of clinical claims without supporting data.
• Replacement of all other labeling requirements by the UDI alone.

Correct Answer: Improved device traceability across supply chains and healthcare settings, facilitating faster recalls, adverse event tracking, and inventory control.

Download